Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (883)	10/31/2001 10:54:54 AM
From: keokalani'nui	Read Replies (1) \| Respond to of 1784

Now this makes sense. Biacore and Bruker Daltonics Announce Strategic Collaboration in Functional Proteomics Joint Development and Co-Marketing of SPR-MS Technology Will Accelerate Proteomic Studies, Leading to Accelerated Target ID for Therapeutics Development UPPSALA, Sweden and BILLERICA, Mass., Oct. 31 /PRNewswire/ -- Biacore International AB (Nasdaq: BCOR - news; SSE: BCOR) and Bruker Daltonics Inc. (Nasdaq: BDAL - news) today announced a new collaboration that aims to advance proteomics research dramatically by associating critical functional information with mass spectrometric identification and characterization of novel proteins critical to the disease process. This collaboration draws upon Biacore's status as a global market leader in providing functional information on biomolecular binding interactions using its proprietary surface plasmon resonance (SPR) technology, and Bruker Daltonics' cutting-edge life-science systems based on mass spectrometry (MS). Together, the companies aim to commercialize the combined technique of SPR-MS in order to create an exciting comprehensive platform for functional proteomics studies. This will help pharmaceutical and biotech companies fast track targets for validation and enable more rapid development of therapeutic compounds.